Krufton (Nilotinib)

Nilotinib inhibits the BCR‑ABL tyrosine kinase by binding to its ATP‑binding pocket, locking the enzyme in an inactive state. This blocks downstream signaling that drives the uncontrolled growth of leukemic cells, leading to reduced proliferation and increased apoptosis of the malignant clone.

The prescribed dose of Krufton is determined by the treating physician based on the patient’s disease phase, prior therapy, and individual tolerance. Dosing adjustments may be required for hepatic impairment or drug‑interaction considerations.

Nilotinib is classified as contraindicated in pregnancy because it may cause fetal harm. Women of childbearing potential should use effective contraception. Breastfeeding is not recommended while receiving nilotinib, as the drug can be excreted in milk and affect the infant.

To place an order, submit an enquiry on the Krufton product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nilotinib is a second‑generation BCR‑ABL inhibitor offering higher potency and selectivity than first‑generation agents such as imatinib. It provides faster and deeper molecular responses, especially in patients resistant or intolerant to earlier TKIs, though safety monitoring for cardiac and metabolic effects is essential.

Krufton should be stored at temperatures below 25 °C, protected from moisture and light. Keep the product in its original container until use, and avoid exposing it to high humidity or direct sunlight to maintain potency.

Krufton is taken orally, usually twice daily on an empty stomach (at least one hour before or two hours after a meal). Tablets should be swallowed whole with a glass of water; they must not be chewed, crushed, or split unless specifically instructed by a healthcare professional.

The most serious adverse events include QT interval prolongation leading to potentially fatal arrhythmias, severe hepatotoxicity, pancreatitis, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for cardiac, hepatic and pancreatic function.

Krufton is contraindicated in patients with a known history of QT prolongation, uncontrolled cardiac disease, or severe hepatic impairment. It should also be avoided in individuals taking strong CYP3A4 inducers or inhibitors that cannot be safely managed, and in pregnant or breastfeeding women.